Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Jurgen Sota; Luciana Breda; Maria Pia Paroli; Soad Hashad; Alejandra de-La-Torre; Silvana Guerriero; Abdurrahman Tufan; Juanita Cardona-López; María José Altamar-García; Saverio La Bella; Antonio Vitale; Edoardo Biancalana; Emanuela Del Giudice; Francesca Minoia; Sulaiman Al-Mayouf; Bruno Frediani; Luca Cantarini; Claudia Fabiani

doi:10.1136/bjo-2025-327410

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Jurgen Sota, Luciana Breda, Maria Pia Paroli, Soad Hashad, Alejandra de-La-Torre, Silvana Guerriero, Abdurrahman Tufan, Juanita Cardona-López, María José Altamar-García, Saverio La Bella, Antonio Vitale, Edoardo Biancalana, Emanuela Del Giudice, Francesca Minoia, Sulaiman Al-Mayouf, Bruno Frediani, Luca Cantarini, Claudia Fabiani

School of Medicine and Health Sciences

Research output: Contribution to journal › Research Article › peer-review

Abstract

To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.

Original language	English (US)
Journal	British Journal of Ophthalmology
DOIs	https://doi.org/10.1136/bjo-2025-327410
State	Accepted/In press - 2025

All Science Journal Classification (ASJC) codes

Ophthalmology
Sensory Systems
Cellular and Molecular Neuroscience

Access to Document

10.1136/bjo-2025-327410

Cite this

Sota, J., Breda, L., Paroli, M. P., Hashad, S., de-La-Torre, A., Guerriero, S., Tufan, A., Cardona-López, J., Altamar-García, M. J., La Bella, S., Vitale, A., Biancalana, E., Del Giudice, E., Minoia, F., Al-Mayouf, S., Frediani, B., Cantarini, L., & Fabiani, C. (Accepted/In press). Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2025-327410

@article{27e361ef1566465eb2350c8ea083db88,

title = "Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders",

abstract = "To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.",

author = "Jurgen Sota and Luciana Breda and Paroli, {Maria Pia} and Soad Hashad and Alejandra de-La-Torre and Silvana Guerriero and Abdurrahman Tufan and Juanita Cardona-L{\'o}pez and Altamar-Garc{\'i}a, {Mar{\'i}a Jos{\'e}} and {La Bella}, Saverio and Antonio Vitale and Edoardo Biancalana and {Del Giudice}, Emanuela and Francesca Minoia and Sulaiman Al-Mayouf and Bruno Frediani and Luca Cantarini and Claudia Fabiani",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.",

year = "2025",

doi = "10.1136/bjo-2025-327410",

language = "English (US)",

journal = "British Journal of Ophthalmology",

issn = "0007-1161",

publisher = "BMJ Publishing Group",

}

Sota, J, Breda, L, Paroli, MP, Hashad, S, de-La-Torre, A, Guerriero, S, Tufan, A, Cardona-López, J, Altamar-García, MJ, La Bella, S, Vitale, A, Biancalana, E, Del Giudice, E, Minoia, F, Al-Mayouf, S, Frediani, B, Cantarini, L & Fabiani, C 2025, 'Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders', British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2025-327410

TY - JOUR

T1 - Tocilizumab effectiveness in paediatric non-infectious uveitis

T2 - data from the International AIDA Network Registries on ocular inflammatory disorders

AU - Sota, Jurgen

AU - Breda, Luciana

AU - Paroli, Maria Pia

AU - Hashad, Soad

AU - de-La-Torre, Alejandra

AU - Guerriero, Silvana

AU - Tufan, Abdurrahman

AU - Cardona-López, Juanita

AU - Altamar-García, María José

AU - La Bella, Saverio

AU - Vitale, Antonio

AU - Biancalana, Edoardo

AU - Del Giudice, Emanuela

AU - Minoia, Francesca

AU - Al-Mayouf, Sulaiman

AU - Frediani, Bruno

AU - Cantarini, Luca

AU - Fabiani, Claudia

PY - 2025

Y1 - 2025

N2 - To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.

AB - To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.

UR - http://www.scopus.com/inward/record.url?scp=105006548868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=105006548868&partnerID=8YFLogxK

U2 - 10.1136/bjo-2025-327410

DO - 10.1136/bjo-2025-327410

M3 - Research Article

AN - SCOPUS:105006548868

SN - 0007-1161

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

ER -

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this